Investigating liver signaling in a common liver disease
Official title: Hepatic TrkB-T1 signaling in NASH pathogenesis and resolution
Funded at University of Michigan at Ann Arbor · NIH-11004316 · Data updated 2026-11-12
This study is looking at how a protein called TrkB-T1 affects the progression of nonalcoholic steatohepatitis (NASH), a serious liver disease, by examining liver samples from both mice and people to find new ways to treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | April 1, 2023 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $540,153 |
| NIH project number | 5R01DK136177-03 |
| Project ID | NIH-11004316 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with nonalcoholic steatohepatitis (NASH) who are experiencing liver inflammation and fibrosis.
✕Less likely to help
Patients with liver diseases caused by alcohol consumption or other non-metabolic factors may not benefit from this research.
What this research studies
This research focuses on understanding nonalcoholic steatohepatitis (NASH), a serious liver disease characterized by inflammation and fibrosis. The team will analyze liver tissue samples from both mice and humans to identify the molecular signals involved in the progression of NASH. By using advanced techniques like bulk and single-cell transcriptomic analysis, they aim to uncover how liver cells communicate and respond to metabolic stress, which could lead to new treatment strategies. The study will specifically look at a protein called TrkB-T1, which may play a critical role in the disease's development.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat or even reverse NASH, improving liver health for many patients.
How similar studies have gone: Previous research has shown promising results in understanding liver signaling pathways in related conditions, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Lin, Jiandie D — University of Michigan at Ann Arbor
- Study coordinator: Lin, Jiandie D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.